These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


208 related items for PubMed ID: 22562956

  • 1. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A, Caviezel C, Pisarsky L, Strittmatter K, García-Echeverría C, Hofmann F, Christofori G.
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [Abstract] [Full Text] [Related]

  • 2. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B, Mancini C, Vitali R, Mancuso M, McDowell HP, Dominici C, Raschellà G.
    Clin Cancer Res; 2006 Nov 15; 12(22):6772-80. PubMed ID: 17121898
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O.
    Eur J Cancer; 2008 Jul 15; 44(11):1577-86. PubMed ID: 18445520
    [Abstract] [Full Text] [Related]

  • 4. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H.
    Biochem Pharmacol; 2006 May 14; 71(10):1435-48. PubMed ID: 16530734
    [Abstract] [Full Text] [Related]

  • 5. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P, Ocio EM, Garayoa M, Montero JC, Hofmann F, García-Echeverría C, Zimmermann J, Pandiella A, San Miguel JF.
    Br J Haematol; 2008 May 14; 141(4):470-82. PubMed ID: 18341634
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
    Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM.
    Leukemia; 2007 May 14; 21(5):886-96. PubMed ID: 17361225
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Piao W, Wang Y, Adachi Y, Yamamoto H, Li R, Imsumran A, Li H, Maehata T, Ii M, Arimura Y, Lee CT, Shinomura Y, Carbone DP, Imai K.
    Mol Cancer Ther; 2008 Jun 14; 7(6):1483-93. PubMed ID: 18566219
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi H.
    Int J Oncol; 2008 Nov 14; 33(5):1107-13. PubMed ID: 18949375
    [Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T, Hartmann W.
    J Pathol; 2008 Dec 14; 216(4):428-39. PubMed ID: 18855347
    [Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
    Attias-Geva Z, Bentov I, Fishman A, Werner H, Bruchim I.
    Gynecol Oncol; 2011 May 01; 121(2):383-9. PubMed ID: 21295335
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Browne BC, Eustace AJ, Kennedy S, O'Brien NA, Pedersen K, McDermott MS, Larkin A, Ballot J, Mahgoub T, Sclafani F, Madden S, Kennedy J, Duffy MJ, Crown J, O'Donovan N.
    Breast Cancer Res Treat; 2012 Dec 01; 136(3):717-27. PubMed ID: 23117852
    [Abstract] [Full Text] [Related]

  • 18. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Baumann P, Hagemeier H, Mandl-Weber S, Franke D, Schmidmaier R.
    Anticancer Drugs; 2009 Apr 01; 20(4):259-66. PubMed ID: 19240643
    [Abstract] [Full Text] [Related]

  • 19. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS, Litz J, Buchdunger E, García-Echeverría C, Hofmann F, Krystal GW.
    Clin Cancer Res; 2005 Feb 15; 11(4):1563-71. PubMed ID: 15746061
    [Abstract] [Full Text] [Related]

  • 20. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.
    Cancer Res; 2003 Feb 01; 63(3):627-35. PubMed ID: 12566306
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.